Original from: QuidelOrtho Fourth Quarter and Full-Year 2024 Results (all comparisons are to the prior year period) Fourth quarter 2024 revenue was $708 million, as reported · Non-respira..

The Nasdaq Hearings Panel has decided to delist T2 Biosystems common stock after the firm failed to meet the stock exchange's requirements for the minimum bid price and market value of listed securities, T2 Biosystems said in a form filed Tuesday with the US Securities and Exchange Commission.

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid has obtained clearance from the U.S. Food and Drug Administration (FDA). This midplex molecular panel tests for 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis — all from one sample, with results available in approximately one hour.

Wantai and UNOPS Partner to Advance Global Tuberculosis Prevention and Control In December 2024, the United Nations Office for Project Services (UNOPS) and Wantai officially signed a long-..

3.4 Genetic Disease Molecular Diagnostic Reagents 3.4.1 Preimplantation Screening Reagent In vitro fertilization embryos are prone to chromosomal aneuploidy abnormalities. Chromosome aneuploidy ref..

Original from: business wire Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ..

MRC Holland said Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR).

Imagene, a leader in AI-powered Oncology Intelligence, today announced a collaboration with Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care. The collaboration aims to advance cancer diagnostics by accelerating biomarker prediction, integrating AI-powered tools into clinical workflows, and enabling the commercialization of accessible diagnostic solutions.

Original from: Illumina · Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% fro..

Original from: Labcorp Company Provides 2025 Guidance · Results from Continuing Operations versus last year: - Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs..

Original from: Siemens Healthineers Siemens Healthineers AG today announces its results for the first quarter of fiscal year 2025 ended December 31, 2024. Q1 Fiscal Year 2025 • ..

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and full-year 2024.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.

AliveDx has obtained a CE mark under the EU’s in vitro diagnostic regulation (IVDR) for the AiPlex connective tissue disease (CTDplus) multiplex assay for use with its MosaiQ planar microarray platform.

Breast Cancer Companion Diagnostic Tests Human epidermal growth factor receptor 2 (HER-2) is an important driver gene and prognostic indicator for breast cancer. It is also a major predictor of anti-HER-2 therap..

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter of 2024.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted.

Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with ENHERTU®. ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.

Diatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA (“Merck”). The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and Africa (MEA) regions.